Larotaxel
Cat. No.：YN270185
| 产品名称: | Larotaxel |
| CAS No.: | 156294-36-9 |
| Chemical Name: | (αR,βS)-β-[[(1,1-Dimethylethoxy)carbonyl]amino]-α-hydroxybenzenepropanoic Acid (1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)-7,12a-Bis(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclodeca |
| Synonyms: | XRP9881 |
| 分子量: | 831.90 |
| 分子式: | C₄₅H₅₃NO₁₄ |
| SMILES: | O=C([C@]1([H])OC(C)=O)[C@@]23[C@@]([C@@H]([C@@]4(O)C(C)(C)C1=C([C@H](OC([C@H](O)[C@H](C5=CC=CC=C5)NC(OC(C)(C)C)=O)=O)C4)C)OC(C6=CC=CC=C6)=O)([H])[C@]7([C@@](OC7)([H])C[C@@H]2C3)OC(C)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Larotaxel (XRP9881) 是一种紫杉烷类似物，具有抗紫杉烷抗性乳腺癌的临床前活性。Larotaxel (XRP9881) 通过促进微管蛋白装配和稳定微管发挥其细胞毒性作用，并最终通过细胞凋亡导致细胞死亡。Larotaxel (XRP9881) 具有穿越血脑屏障的能力，对 P-糖蛋白 1 的亲和力比 Docetaxel 低得多。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Kurata, T., et al.: J. Clin. Oncol., 18, 3164 (2000), Kemper, E., et al.: Eur. J. Cancer, 40, 1269 (2004), Nyman, D., et al.: J. Clin. Oncol., 23, 7785 (2005),
